Testosterone Injections vs Gel: Which TRT Format Fits You?

Testosterone injections and FDA-approved gel can both raise testosterone when treatment is appropriate, but neither is universally better. Injections avoid daily skin application and secondary-transfer precautions; gel avoids needles and provides daily transdermal dosing. The better fit depends on the exact product, household, routine, monitoring results, fertility plans, cost and clinician assessment.

Best fit for injections if: avoiding daily topical application and household-transfer precautions matters more to you than avoiding needles.

Best fit for gel if: avoiding injections matters more to you than managing a daily application routine and transfer precautions.

Not a format-choice problem yet if: low testosterone has not been properly confirmed, near-term fertility is important, or a clinician has not yet evaluated whether testosterone treatment is appropriate.

We read the current prescribing information for every product named on this page in September 2026. Two FDA labeling changes from 2025 and 2026 make several older comparison articles stale, so this page separates current class-wide FDA actions from product-specific labels that have not all updated on the same timeline.

Testosterone injections vs gel: the honest comparison table

Answer: Testosterone injections vs gel is not a simple “stronger versus weaker” choice. The formats differ most in routine, transfer risk, needles, absorption, blood-test timing, product-specific warnings, and cost. Trial and blood-pressure numbers from different products should not be treated as a head-to-head contest.

Those representative trial numbers come from two separate studies, not a head-to-head race. They are useful for understanding how each product was studied, but they cannot establish that injections as a class are more effective than gels as a class.

The right TRT provider is not the same for every person — it depends on whether low testosterone has been properly evaluated, your symptoms and health history, your fertility plans, your state, your insurance or cash-pay preference, your treatment-format preference, your budget, and whether online or in-person care is the better starting point. Some situations belong with primary care, urology, endocrinology, reproductive urology, or urgent or emergency care when the symptoms warrant it. Because a general answer cannot resolve those for you, use TRT Provider Guide's Find My TRT Path tool to map your situation to the right care route and the questions to ask before you pay. The tool is educational and non-diagnostic.

TRT Provider Guide is the independent decision resource for testosterone replacement therapy — helping U.S. adults understand how low testosterone is evaluated, compare online and local care models and providers, and choose the next step that fits their health needs, fertility plans, budget, state, and care preferences, with every material claim verified and dated.

Which one has a boxed warning now? The story changed in July 2025

Answer: As of the labels posted in September 2026, AndroGel 1.62% carries an FDA boxed warning for secondary exposure — testosterone transferring from treated skin to another person. XYOSTED's boxed warning for blood-pressure increases was removed in July 2025, while current testosterone cypionate labeling has no boxed warning. AVEED is the important exception among injections: it retains a boxed warning for serious pulmonary oil microembolism and anaphylaxis.

A boxed warning is the strongest warning the FDA can put on a prescription drug. It sits in a black box at the very top of the label. When people say "black box warning," this is what they mean.

Here's what the labels actually say right now. We pulled each one ourselves.

So if you're choosing between a vial of cypionate and a pump of gel, the gel is the one with the black box.

Now the part where we argue against ourselves. A boxed warning measures one specific hazard. It is not a total risk score. The gel's warning is about harm to other people. The injection's biggest risks — red blood cell count and blood pressure — are real, they're on the label, they're just not in a box. Don't let a black box do your thinking for you. Use it as one input, not the verdict.

---

What the FDA changed in 2025 — and changed again in June 2026

Answer: The FDA made two separate labeling moves. In February 2025 it removed boxed-warning language about increased cardiovascular risk from testosterone-product labeling and required blood-pressure information. In June 2026 it requested removal of the age-related-hypogonadism limitation of use and revisions to prostate-cancer and benign-prostatic-hyperplasia information.

This is the most current thing on this page, and it's the reason a comparison article written six months ago is already out of date.

February 28, 2025. After reviewing the TRAVERSE trial and required blood pressure monitoring studies, the FDA told manufacturers to add TRAVERSE results to all testosterone labels, remove the boxed-warning language about increased cardiovascular risk, and add blood pressure warnings. At that point it explicitly said it was keeping the "limitation of use" language about age-related low testosterone.

June 18, 2026. Sixteen months later, the FDA reversed that last piece. It announced it was requesting three changes:

• Remove the limitation of use stating that safety and effectiveness of testosterone therapy in men with age-related low testosterone have not been established
• Update information related to prostate cancer risk
• Revise the warnings about benign prostatic hyperplasia, the non-cancerous enlarged prostate

Under the requested revisions, testosterone therapy would be contraindicated only in men with metastatic prostate cancer, rather than in anyone with known or suspected prostate cancer. The FDA also said available trial data don't show worsening symptoms in men with mild to moderate enlarged prostate, though evidence is still limited for men with severe symptoms. Its recommendation there is continued monitoring.

The agency was careful about what it did not claim. Prostate cancer takes years to develop, and existing studies may not have followed men long enough to catch long-term effects. Screening before treatment and monitoring during treatment are still recommended.

Here's the part that will confuse you at the pharmacy

The labels haven't all caught up. The FDA requested these updates in June 2026. Individual products update on their own timelines.

When we checked on September 18, 2026, the posted prescribing information for AndroGel 1.62% (revised July 2025) and XYOSTED (revised July 2025) still contained the age-related limitation of use — the exact sentence the FDA asked to have removed.

That is not a conspiracy. That's how drug labeling works. But it means you can read a news story in June, then read your Medication Guide in September, and get two different messages.

What to do with that: read the current FDA-approved label for the exact product you receive, and know that FDA's June 2026 announcement describes requested class-wide revisions that may not yet appear in every posted product label. If the two seem inconsistent, ask the prescriber or pharmacist which current instructions apply to your product.

And one honest limit. None of this changes the injections-versus-gel decision much. These changes are class-wide. They apply to both formats equally. Anyone telling you the June 2026 news makes one format the winner is selling something.

---

Which one actually gets your testosterone into a normal range?

Answer: Both FDA-approved injection and gel products can raise testosterone into their study-defined target ranges, but the percentages from separate pivotal trials cannot tell you which format will work better for you. XYOSTED and AndroGel 1.62% were studied in different trials with different designs, schedules and participants.

Here's what we assembled by placing the two pivotal trials side by side. We did the work of pulling both labels so you don't have to open six PDFs.

Read that comparison carefully, because it cuts both ways. The injection trial had a higher percentage in its protocol-defined range at its primary endpoint, and the gel trial had more participants with a Cmax above 1,500 ng/dL. But these were not the same men, the same study, or the same protocol. You cannot subtract one percentage from the other and call the result a treatment advantage.

What we actually know about poor response to gel

Skin absorption can vary between people. A 2008 retrospective study reviewed 370 men using AndroGel or Testim; 75 men — 20% of that clinic cohort — switched gel brands because of a suboptimal initial biochemical or symptomatic response. Among men switching from AndroGel to Testim, 58% were below 300 ng/dL before the switch and 17% remained below 300 ng/dL afterward.

That does not mean one in five gel users today will fail treatment. The study was retrospective, involved older gel products and a selected group of men treated in one clinical setting. What it does show is that a poor response to one gel is possible and that product-specific absorption matters.

The early follow-up point

You don't have to judge a gel only by how you feel.

The AndroGel 1.62% label used morning pre-dose testosterone measurements around days 14 and 28 for dose titration in its pivotal study. Specialty guidance also calls for follow-up testing after treatment begins, with timing matched to the formulation.

Translation: gel response can be checked early with correctly timed blood work. Injection monitoring also has to be timed to the exact product and dosing interval. A disappointing number without the timing and product context can be misleading.

If a follow-up level is not where the prescriber expected despite correct use, that is a reason to review the exact product, technique, adherence, timing and other treatment options with the clinician — not a reason to assume testosterone treatment as a whole has failed.

Which one gives steadier levels?

Answer: Daily gel generally creates a more continuous exposure pattern, while short-acting injections can produce a larger difference between post-dose and pre-dose levels. How large that swing is depends on the exact injectable product, prescribed interval, individual pharmacokinetics and when the blood sample is taken.

Here's the pharmacology in plain terms.

Gel is absorbed through the skin during daily use. AndroGel 1.62% labeling describes testosterone concentrations returning toward baseline within roughly 48 to 72 hours after the last dose, which is why missed applications can matter.

Injections create a depot or other product-specific release pattern. XYOSTED, for example, is a once-weekly subcutaneous testosterone enanthate product and its label adjusts treatment using a trough level measured seven days after the most recent dose. Intramuscular testosterone cypionate is a different product with a different label.

But here's the honest caveat. "Steadier" is only useful if the exposure is appropriate and the routine is one you can follow. A daily gel used inconsistently can be less reliable than a prescribed injection schedule followed consistently, and an injection schedule changed without clinician guidance can make both symptoms and lab interpretation harder.

How serious is testosterone gel transfer, really? (With the actual numbers)

Answer: It's serious enough to carry a boxed warning, and the FDA label measured exactly how much transfers under different conditions. Fifteen minutes of skin contact with an uncovered application site raised a female partner's testosterone by 280%. With a t-shirt over the site, the same contact raised it by 6%. The risk is real and it is almost entirely controlled by two habits.

This is the part of the decision people are most afraid of and least informed about. Every other page says "it can transfer, wash your hands." The label ran actual studies. Here they are.

Three things fall out of that table that nobody else is telling you.

One: a t-shirt does most of the work. It takes transfer from +280% to +6%. That's not a small improvement. That's the difference between a real exposure and background noise.

Two: a t-shirt does not rescue a wrong application site. Applied to the abdomen under a shirt, transfer still ran +43% on day one and climbed to +60% by day seven. Where you put it matters more than what you cover it with. The 1.62% label allows only the shoulders and upper arms — inside the area a short-sleeve t-shirt covers. Not the stomach, not the chest, not the armpits, not the genitals, not the knees.

Three: the two gel strengths have different rules. The 1.62% label allows shoulders and upper arms only. Common 1% labels also allow the abdomen. Instructions from one gel are not safe to apply to another, and the 1.62% label says so directly — its application site and dose are not substitutable with other topical testosterone products.

What actually happened to the children

We're not going to soften this part.

The FDA has received post-marketing reports of children showing signs of virilization after contact with treated skin — enlarged penis or clitoris, early pubic hair, increased erections and libido, aggressive behavior, and advanced bone age. In most reported cases, these regressed once the exposure stopped.

In a few cases, they did not. Enlarged genitals did not fully return to normal size, and bone age remained ahead of chronological age.

The label also notes at least one report where the person filing it considered transfer from the user's shirts, towels or sheets to be possible — not just direct skin contact.

Showering, swimming, the gym

You can shower on gel. You just have to wait.

The 1.62% label says wait at least two hours before swimming, showering or washing the site. Showering at 2 hours cut absorption by about 13%. At 6 hours, about 12%. At 10 hours, there was no measurable effect at all. One common 1% label calls for at least five hours. Use the number on the product you were actually given.

Two smaller details from the same label section, because they surprise people:

• Moisturizer applied over the site an hour later increased absorption by about 14%. Sunscreen increased it about 8%.
• Alcohol-based gel is flammable until dry. If you smoke, weld, or cook over a gas flame, that's a real consideration and not a technicality.

The paragraph where we tell some of you to pick the other one

If you have a toddler who climbs on you the second you get dressed, or a partner who's pregnant or trying to be, be honest with yourself about whether you'll run this routine perfectly every morning for years. Not most mornings. Every morning.

If the answer is no, that isn't a character flaw. It's a good reason to choose the format that doesn't ask it of you.

---

If household transfer is the thing that rules out gel for you, the next question is whether an injection fits your health history, routine and monitoring plan. Map your situation with Find My TRT Path — it is free, educational and non-diagnostic, and it helps you identify the questions to ask before choosing a care route.

---

Do injections raise red blood cell counts more than gel?

Answer: Probably yes, but the evidence is softer than the internet claims. Observational studies consistently find higher rates with injections. Randomized trials, pooled together, found a smaller difference that did not reach statistical significance between gel and injection. Either format requires monitoring.

Hematocrit is the share of your blood made up of red blood cells. Testosterone can raise it. A high hematocrit raises concern about blood viscosity and thromboembolic risk, although the exact risk attributable to testosterone-induced erythrocytosis is not fully settled.

This is where most comparison pages overstate their case, so we're going to show you both bodies of evidence and let you see why they disagree.

What the randomized trials show. A Bayesian network meta-analysis pooled randomized controlled trials and calculated the average hematocrit increase against placebo for each format:

Every format raised hematocrit. But when the analysis compared formats against each other, the only statistically significant difference was intramuscular enanthate/cypionate versus the patch. Gel versus injection did not reach significance.

What the observational studies show. Larger real-world reviews tell a stronger story. A systematic review in Blood Advances found intramuscular formulations associated with higher rates of erythrocytosis — abnormally high red cell mass — and higher hemoglobin and hematocrit than pellet and topical formulations, with reported rates across studies ranging from 0% to 66.7%. Higher doses produced higher counts. Older men were at higher risk.

The AUA guideline cites a retrospective series reporting polycythemia in 19% of men on intramuscular testosterone, 12.5% on pellets, and 5.4% on gels.

Why do these disagree? Observational studies aren't randomized. The men who choose or get prescribed injections aren't the same as the men on gel — they often start with different baseline counts, different ages, and different doses. Randomized trials control for that but tend to be shorter and smaller.

The defensible conclusion: injections probably do raise hematocrit more. The evidence for "much more" is weaker than it's usually presented. Neither format lets you skip blood counts.

What the labels say about monitoring

The XYOSTED label directs checking hematocrit about every three months. The AndroGel label suggests checking before starting, re-checking at 3 to 6 months, then annually. The AUA guideline says a hematocrit of 54% or higher warrants clinician intervention.

For scale, in the XYOSTED trials, hematocrit reached 55% or higher in 4.2% of men, and the average increase was 3.8 percentage points at six months and 5.4 at one year.

Our full TRT blood test guide covers what a complete monitoring panel should include.

---

What side effects are actually different between the two?

Answer: Many systemic testosterone risks overlap, but the formats also have product-specific risks. Injectable formulations tend to raise hematocrit more on average; gel has a unique secondary-transfer risk; and both injection and gel products can raise blood pressure. Local reactions also differ — skin irritation on one side, injection-site reactions on the other.

Here's product-specific trial and monitoring data from the AndroGel 1.62% and XYOSTED labels, side by side. These were different studies with different sizes, lengths and populations. The table shows each product's profile; it does not prove that all injections are riskier than all gels.

The mood signal on XYOSTED

We're flagging this plainly because it's on the label and it deserves to be seen before you choose.

The XYOSTED label carries a Section 5.15 warning for depression and suicidal thoughts and behavior, including completed suicide, observed during its clinical trials. Across the 283 men in the two studies, four — 1.4% — were affected: two discontinued for depression, and two made suicide attempts, one of which was completed.

That warning is specific to that product. It does not appear on the gel labels or the cypionate label. It is not a reason to rule out injections. It is a reason to tell your prescriber immediately if your mood changes on any testosterone therapy.

If you're having thoughts of harming yourself, call or text 988 in the U.S. right now. Don't wait for an appointment.

Risks that come with either one

Both formats carry the systemic risks of testosterone: rising red cell counts, rising blood pressure, suppressed sperm production, acne, breast tenderness or enlargement, fluid retention, worsening sleep apnea in men at risk, prostate and urinary changes requiring monitoring, reports of blood clots in deep veins and lungs, and the potential for misuse.

Our TRT side effects guide goes deeper on each.

One small thing that becomes a big thing: what's in the oil

Nobody puts this in a table, so we did.

If you have a sesame allergy, say so before anyone hands you an auto-injector. If you have a cottonseed allergy, say so before anyone hands you a vial of cypionate. This is a two-second conversation that prevents a real problem.

---

Why does my doctor say every two weeks when everyone online says weekly?

Answer: Because product labeling, specialty guidance and real-world prescribing are not the same document. Depo-Testosterone is labeled for intramuscular use, while XYOSTED is a separate FDA-approved testosterone enanthate product labeled for once-weekly subcutaneous use. A clinician may prescribe an FDA-approved drug off label, but that does not turn an off-label route or schedule into the product's FDA-approved instructions.

This confuses more men than almost anything else in TRT, so here it is straight.

What matters is knowing which product you were prescribed, which route the label uses, what your clinician prescribed, and when your labs are supposed to be drawn.

Dosing decisions belong to your prescriber. This page does not give a dose, injection interval or self-injection protocol, and you should not change one based on a forum or comparison chart.

Which costs less: testosterone injections or gel?

Answer: Generic injectable testosterone is often cheaper at the pharmacy than an FDA-approved testosterone gel, but there is no universal monthly-price ratio. The real bill depends on the exact product, quantity, pharmacy, insurance or discount program, injection supplies, laboratory work, clinician fees and whether care is bundled into a membership.

This is where a simple "$6 injection versus $40 gel" comparison breaks down. A vial price is not automatically a monthly treatment cost, and a pump price is not automatically one month for every prescription. Discount-card prices also change by pharmacy, location, quantity and manufacturer.

Compare the bill in the same units

Before price decides the format, get these numbers for the exact prescription:

Brand versus generic can be a bigger swing than treatment format. If a clinician prescribes gel, compare the exact generic and brand products your plan or pharmacy can dispense. If a clinician prescribes an injectable product, compare the exact vial or device — not a different formulation with a different schedule.

The medicine may not be the biggest line on the bill. Telehealth membership fees, consultations, lab panels, repeat testing and shipping can exceed the pharmacy price of generic medication. Our TRT cost guide breaks down complete first-year cost by care model.

Before you let price decide

Insurance can reverse the cash-price comparison. Formularies may cover one testosterone product and restrict another through prior authorization, step therapy, quantity limits or a higher tier.

Check the exact product on your formulary and ask the pharmacy for the current price before treating any internet number as your price. GoodRx itself says displayed cash and discount prices can change and should be checked for the exact drug, form, strength, quantity and pharmacy.

Does gel or injection affect fertility differently?

Answer: No formulation should be treated as fertility-protective. Exogenous testosterone can suppress sperm production through the same hormonal feedback pathway whether it is delivered by injection or gel. Choosing gel instead of an injection does not remove that concern.

Here's the mechanism in plain language. Testosterone you take from outside the body signals your brain to stop sending the hormones — luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — that tell your testicles to make testosterone and sperm. Your blood testosterone can look perfect while sperm production has shut down.

Current testosterone labeling warns that exogenous testosterone can suppress spermatogenesis — sperm production — and that reduced fertility or infertility can occur. Recovery after stopping varies, so this page does not promise either infertility or fertility recovery on a fixed timeline.

How complete is the suppression? World Health Organization trials that used weekly intramuscular testosterone enanthate as a male contraceptive suppressed sperm counts to zero or near-zero in about 97% of men at six months. That was a male-contraception study with its own regimen and population, so don't read the exact percentage as your personal forecast. The mechanism is the point.

The guidelines are unusually direct here. AUA Statement 23 is a Strong Recommendation with Grade A evidence: exogenous testosterone should not be prescribed to men who are currently trying to conceive. The Endocrine Society recommends against starting testosterone therapy in men planning fertility in the near term. AUA Statement 10 says men interested in fertility should have a reproductive health evaluation before treatment.

If this is you, here's your actual next step

Not an online TRT program of either format.

The right first call is a urologist, a reproductive urologist, or a fertility-aware endocrinologist. Depending on your situation that may mean a semen analysis, reproductive hormone testing, a review of medications and reversible causes, sperm banking, or a fertility-directed treatment plan instead of routine TRT.

The AUA notes that clinicians may use aromatase inhibitors, human chorionic gonadotropin (hCG), or selective estrogen receptor modulators in men who want to maintain fertility. Those are different medicines with different evidence. They are not TRT, and nobody should be calling them "natural testosterone therapy." Recovery after stopping testosterone varies and should never be promised on a fixed timeline.

Our full TRT and fertility guide covers this properly.

---

Is the "testosterone cream" online clinics sell the same as testosterone gel?

Answer: Usually not, and this trips up a lot of men comparing options online. The gels in this comparison — AndroGel, Testim, Vogelxo, Fortesta and their generics — are FDA-approved products with published labels, clinical trial data and a boxed warning. Most daily topicals sold by online TRT companies are compounded creams mixed by a compounding pharmacy, which are not FDA-approved and have no equivalent label or trial data behind them.

Compounding can serve a real medical need when applicable federal and state requirements are met — for example, when an FDA-approved product cannot meet a patient's specific need. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before marketing.

What it is not: FDA-approved, generic, "the same thing," bioidentical in any regulatory sense, safer, more natural, or clinically proven. The FDA does not review compounded drugs for safety, effectiveness or quality before they're marketed.

The AUA addresses this directly. Statement 28 says commercially manufactured testosterone products should be prescribed rather than compounded testosterone when possible. That's a Conditional Recommendation on Grade C evidence — a preference, not a prohibition. We're reporting it accurately rather than inflating it.

Here's the practical consequence for everything you just read. The transference numbers, the 81.6% response rate, the adverse event rates in our tables — all of that comes from the FDA-approved gel's trials. None of it automatically applies to a compounded cream. A compounded cream might transfer more or less. Nobody has published that study.

If you're offered a topical, ask four questions before you pay:

1. Is this an FDA-approved product or a compounded preparation?
2. Which pharmacy compounds it, and is it a 503A or 503B facility?
3. What's the exact concentration, and how many milligrams come from one pump?
4. What evidence supports this specific formulation?

---

How blood test timing differs — and why online lab comparisons mislead you

Answer: The right time to draw blood depends on the exact product and schedule. A level drawn at the wrong point in a dosing cycle answers a different question than the one your clinician asked. This is why comparing your number to a stranger's number on a forum is close to meaningless.

This is a genuinely underrated difference between the two formats, and it explains a lot of confusion.

Think about what that means. A man on weekly injections who tests the day after his shot and a man who tests the day before his next one can be on the identical protocol and post wildly different numbers online. Neither is lying. They measured different parts of the same wave.

Gel doesn't have that problem in the same way, because daily dosing flattens the curve — but it has its own: your number depends on whether you applied it that morning, whether you showered too soon, whether you put it on the right site, and whether you missed any days that week.

What to bring to a follow-up appointment. For injections: the exact product and ester, the dose in both milligrams and milliliters, the route, the interval, and the date and time of both your last dose and the blood draw. For gel: the product and concentration, the number of pumps or packets, the application time and site, the time between application and the draw, and any missed doses.

A result without that context isn't a result. It's a number.

---

Which one is easier to actually live with?

Answer: The answer depends less on abstract convenience and more on which inconvenience you can reliably manage — needles and a scheduled shot, or a daily skin routine with contact precautions. Both are manageable. Neither is nothing.

Find yourself in this table. It's a starting point for a clinician conversation, not a prescription.

Notice how many rows end in "neither." That's not us hedging. The AUA requires two separate early-morning testosterone measurements plus symptoms or signs before a diagnosis is made. Every product label in this comparison says the same thing in its dosing section. If a program skipped that, format is not your problem.

---

Can you switch from gel to injections, or back?

Answer: A clinician can switch a patient between testosterone formulations when there is a medical or practical reason, but the products are not dose-for-dose interchangeable. The dose, timing and monitoring plan can change with the formulation, so switching belongs with the prescriber rather than a self-conversion chart.

Real reasons men switch: injection site pain, needle anxiety, peak-and-trough symptoms, rising hematocrit, persistent skin irritation, poor absorption despite correct use, repeatedly missed daily doses, household transfer risk, insurance or pharmacy changes, or a schedule that stopped working.

Four things a safe switch has to answer:

1. When does the old product stop mattering? A depot injection keeps releasing after the day it's given. Gel levels fall over 48 to 72 hours.
2. When does the new one start? Overlap or a gap changes your exposure.
3. When is the first level checked? The new format needs enough consistent use for the result to mean anything.
4. What safety training changes? Switching to gel means transfer training. Switching to injections means injection and sharps training.

Do not use a conversion chart from a forum. There is no safe milligram-for-milligram conversion between formats. Only about 10% of applied gel is absorbed, and injectable esters aren't pure testosterone by weight — an ester is a chemical form attached to the hormone to slow its release, and it adds molecular weight that isn't testosterone. That's why 81 mg of gel and 100 mg of cypionate aren't comparable numbers, and why "100 mg is 100 mg" is wrong.

Even gel-to-gel isn't a straight swap. The 1.62% label says its application site and dose are not substitutable with other topical testosterone products.

---

Where do you actually get each format?

Answer: Both formats require a valid prescription, but the most direct care path can differ. FDA-approved testosterone gel is commonly filled through a retail or mail pharmacy after a clinician prescribes the exact product. Injectable testosterone may also be filled by a pharmacy, supplied through a telehealth program, or administered in a clinic depending on the product.

If you want an FDA-approved gel

Start with the prescriber and pharmacy path. Ask for:

• The exact gel product and strength
• Whether the prescription is brand or generic
• The allowed application sites and contact precautions for that exact label
• The formulary or prior-authorization requirements
• The current pharmacy price
• The follow-up lab plan

A membership program is not automatically better just because it advertises "topical testosterone." Many online TRT programs use compounded cream rather than an FDA-approved gel, and those are not interchangeable categories.

If you want injections

Ask whether the proposed product is:

• A pharmacy-dispensed testosterone cypionate or enanthate product
• A labeled subcutaneous product such as XYOSTED
• A long-acting clinic-administered product such as AVEED
• A compounded preparation

Then ask who supplies it, which pharmacy is involved, what the labeled route is, what training is provided, and how laboratory results and adverse effects are handled.

What current online programs publicly list

Public provider pages checked in September 2026 show that Male Excel advertises testosterone cypionate injections and a compounded Lipoderm testosterone cream, not an FDA-approved testosterone gel. Male Excel's main pricing page currently lists a required $99 monthly medical membership, medication priced separately, and injections starting at $120 a month plus shipping; its own older subdomain shows conflicting lower pricing, so readers should not assume the lower schedule applies to new enrollment.

Hone Health currently lists testosterone cypionate injection, compounded testosterone cream and compounded testosterone troches for men. Its public medication menu does not list a standard FDA-approved testosterone gel.

Affiliate disclosure: TRT Provider Guide may earn compensation through certain provider links. Read our full affiliate disclosure. Provider examples above are included only to show why "topical testosterone" and "FDA-approved gel" cannot be treated as the same shopping category.

Before you pay anyone, get these in writing

Prices, included labs, state coverage and program terms change. Ask for:

• The exact medication, whether it is FDA-approved or compounded, and which pharmacy dispenses it
• Complete first-year cost: medication, membership, labs, repeat labs, shipping and consult fees
• The full lab schedule, including hematocrit and blood-pressure follow-up
• What happens if a result is abnormal
• Whether the program serves your state for the specific service you need
• Cancellation terms, refund policy and how you obtain your medical records

A program that cannot answer those before taking payment has not told you enough to compare it fairly.

Still deciding? Map your situation with Find My TRT Path — it is free, educational and non-diagnostic, and it helps you identify the questions to sort out before you pay.

Can you get testosterone injections or gel legally online?

Answer: Yes, telemedicine can still be used for controlled-substance prescribing when federal and state requirements are satisfied, but testosterone remains a Schedule III controlled substance and requires a valid prescription from an appropriately licensed clinician. Federal flexibilities do not erase state licensing, prescribing, standard-of-care or product-specific requirements.

There is no lawful retail shortcut around the prescription requirement. A seller offering prescription testosterone without a valid prescription is not providing lawful U.S. prescription care.

Federal telemedicine flexibilities that allow remote prescribing of controlled medications without a prior in-person visit currently run through December 31, 2026, under the fourth temporary extension issued jointly by the DEA and HHS, effective January 1, 2026. A permanent framework is still pending. State rules vary and some are stricter than the federal floor.

If you're reading this after 2026, check the current rule before assuming online prescribing works the way it does today.

---

What we actually verified

Answer: We checked the comparison against current FDA safety actions, current U.S. prescribing information for representative injection and gel products, DEA controlled-substance information, the current federal telemedicine extension, major specialty guidance, peer-reviewed comparative evidence, and the public provider pages used in the access section.

Verification date: September 18, 2026

What this page does not establish

That one format is universally safer, more effective or better for every man. That the trial numbers from separate studies can be subtracted from each other. That observational hematocrit rates predict your personal risk. That a provider's advertised price is your final bill.

We don't convert doses, recommend an injection interval, or interpret anyone's labs. Inclusion of a provider is not an endorsement, and we do not assign a treatment format a numeric medical score.

Frequently asked questions

Answer: The most common follow-up questions are about effectiveness, transfer, hematocrit, blood pressure, fertility, switching, insurance and monitoring. The answers below stay product-specific where the evidence is product-specific and avoid turning one study or label into a universal rule.

Is testosterone gel as effective as injections?

Both formats can raise testosterone into an appropriate range when they are correctly prescribed and monitored. Separate pivotal trials reported 90% in range for XYOSTED at week 12 and 81.6% for AndroGel 1.62% at day 112, but those percentages came from different studies and cannot establish that injections are more effective as a class.

Do injections work faster than gel?

The answer is product-specific. AndroGel 1.62% reaches a steady exposure pattern within days, while XYOSTED labeling reports steady state after several weeks; other injectable products have different pharmacokinetics. How quickly symptoms change is separate from how quickly blood concentrations reach a steady pattern and varies by person.

Is testosterone gel dangerous for children?

Secondary exposure can be harmful. Current gel labeling reports virilization in children after contact with treated skin. Product-specific transfer studies also show that covering the application site greatly reduces transfer, but does not make the risk zero.

Can I shower after applying testosterone gel?

Follow the exact product label. AndroGel 1.62% says to wait at least two hours before showering or swimming; other testosterone gels can have different waiting periods. Do not copy one gel's instructions to another.

Can I go to the gym or swim on gel?

Follow the product-specific waiting period for washing or swimming and prevent direct skin contact with the application site until the label's precautions are satisfied. If another person's skin may touch the site, follow the label's washing and covering instructions first.

Do testosterone injections have to go in the gluteal muscle?

Not every injection uses the same route. Current Depo-Testosterone labeling specifies deep intramuscular gluteal administration, while XYOSTED is labeled for subcutaneous abdominal use. Follow the instructions for the exact product prescribed.

Which raises hematocrit more?

Injectable testosterone tends to raise hematocrit more on average. A randomized-trial network meta-analysis found mean increases versus placebo of 3.0 percentage points for gel and 4.0 for intramuscular enanthate/cypionate, but the difference between those two formulations was not statistically significant in the network comparison. Observational evidence shows a stronger association with intramuscular products. Either format requires monitoring.

Does insurance cover gel or injections?

Coverage varies by plan and exact product. One plan may prefer a generic injectable product while another may cover a gel more favorably or require prior authorization. Check the formulary for the exact prescription rather than assuming one format is always cheaper.

Can I switch from gel to injections?

Yes, clinicians can switch formulations when there is a medical or practical reason. There is no safe universal milligram-for-milligram conversion, and the monitoring timing changes with the product, so the switch belongs with the prescriber.

Is compounded testosterone cream the same as AndroGel?

No. Compounded testosterone cream is not an FDA-approved finished drug product and does not automatically share the dosing, transfer, pharmacokinetic or clinical-trial data of AndroGel or another approved gel.

Will TRT make me infertile?

Exogenous testosterone can suppress sperm production, but the degree and recovery vary. If future fertility matters — especially if you are trying to conceive now or soon — discuss that before starting testosterone with a urologist, reproductive urologist, endocrinologist or another fertility-aware clinician. Do not assume gel protects fertility compared with injections.

How often do I need blood tests?

The schedule depends on the product, stage of treatment and clinical situation. Testosterone, hematocrit and other monitoring are checked at formulation-specific times after treatment starts or changes, and then periodically. PSA or other prostate monitoring depends on age, risk and clinician judgment rather than one universal schedule.

What if I have a sesame allergy?

XYOSTED is formulated with sesame oil and its labeling lists hypersensitivity to XYOSTED or its ingredients as a contraindication. Depo-Testosterone uses cottonseed oil. Tell the prescriber and pharmacist about relevant allergies before using an injectable product.

Do I really need two blood tests before starting?

For diagnosing testosterone deficiency, AUA guidance calls for two total-testosterone measurements on separate occasions, both obtained in the early morning, together with symptoms or signs. The Endocrine Society likewise recommends symptoms/signs plus consistently low testosterone and confirmation with a repeat morning fasting measurement.

Is gel safer because it's "more natural"?

No. "Natural" is not a meaningful safety category here. FDA-approved gels and injection products each have systemic testosterone risks plus product-specific risks, and neither should be treated as automatically safer because of how it is delivered.

Which is safer if I have heart disease?

There is no universal route winner. TRAVERSE found major cardiovascular events in 7.0% of the AndroGel 1.62% group and 7.3% of the placebo group in a population with cardiovascular disease or risk factors, but that trial studied gel versus placebo — not gel versus injections. A clinician should assess recent cardiovascular events, blood pressure and the rest of the risk picture before treatment.

Can I stop either one suddenly?

Do not change or stop prescribed testosterone based on a comparison article. A depot injection and a daily gel leave the body on different timelines, and the reason for treatment still needs a plan. Contact the prescriber for product-specific guidance; seek urgent or emergency care for serious symptoms.

---

The bottom line

Answer: Testosterone injections and FDA-approved gel are both legitimate prescription formats, and neither is universally better. The useful choice is the exact product that fits the patient's clinical plan, household, routine, monitoring needs, fertility goals and cost without creating a burden they are unlikely to manage consistently.

They fail differently rather than one being universally better.

Injections avoid daily skin application and secondary-transfer precautions. They also involve needles or clinic administration, product-specific injection risks, sharps or device handling, and a greater tendency toward hematocrit rise on average.

Gel avoids needles and usually produces a more continuous daily exposure pattern. It also requires a daily application routine, product-specific skin instructions and secondary-exposure precautions, and some people do not achieve the expected level on a given gel.

Pick the inconvenience and safety routine you can actually manage after the medical decision has been made. That's the real comparison.

And if you're still in the "I don't know if I even need this yet" stage — that's the most useful place to be, not the least. Get the diagnosis confirmed properly first. The format question is easier once that's settled.

Educational notice: This page is educational information from TRT Provider Guide, the independent decision resource for testosterone replacement therapy care. It is not medical advice, a diagnosis, an interpretation of your labs, or a recommendation for any product or dose. TRT Provider Guide is not a clinic, pharmacy, laboratory, insurer, or medical practice. Testosterone is a Schedule III controlled substance and requires a valid prescription.

Seek urgent or emergency care for chest pain, sudden trouble breathing, coughing up blood, one-sided leg swelling or pain, sudden weakness, facial droop, trouble speaking, fainting, or a severe allergic reaction. For accidental gel exposure, wash the exposed skin with soap and water right away and contact a healthcare professional if a child or pregnant person was exposed or if signs of androgen effects appear. If you are having thoughts of harming yourself, call or text 988 in the United States.

Still not sure which TRT care route fits you? Use our free Find My TRT Path tool. It's educational and non-diagnostic.

---

Sources

Source note: Consequential medical and regulatory claims above are tied to FDA labeling, FDA/DEA/HHS material, specialty guidance or peer-reviewed evidence. Commercial facts are labeled as provider-stated and were checked against the provider's own public pages.

All sources accessed and verified September 18, 2026 unless another access date is stated.

1. U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. February 28, 2025.
2. U.S. Food and Drug Administration. Testosterone Information. Updated June 2026.
3. U.S. Department of Health and Human Services. HHS Announces Requested Updates to Testosterone Therapy Product Labels. June 18, 2026.
4. U.S. Food and Drug Administration. AndroGel 1.62% prescribing information. Revised July 2025.
5. U.S. Food and Drug Administration. XYOSTED prescribing information. Revised July 2025.
6. DailyMed. DEPO-TESTOSTERONE (testosterone cypionate) prescribing information. Updated September 2025.
7. DailyMed. AVEED (testosterone undecanoate) prescribing information. Current label checked September 2026.
8. American Urological Association. Evaluation and Management of Testosterone Deficiency Guideline. Published 2018; validity confirmed 2024.
9. Endocrine Society. Testosterone Therapy for Hypogonadism Guideline Resources. Guideline published 2018.
10. Nackeeran S, Kohn T, Gonzalez D, et al. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. Journal of Urology. 2022;207(1):44-51.
11. Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review. Blood Advances. 2025;9(9):2108-2118.
12. Grober ED, Khera M, Soni SD, et al. Efficacy of changing testosterone gel preparations among suboptimally responsive hypogonadal men. International Journal of Impotence Research. 2008;20(2):213-217.
13. Drug Enforcement Administration. Drug Scheduling. Testosterone is listed among Schedule III examples.
14. Drug Enforcement Administration and Department of Health and Human Services. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Effective January 1, 2026 through December 31, 2026.
15. Male Excel. TRT cost and program information. Provider-stated commercial information checked September 18, 2026.
16. Male Excel. TRT Online. Provider-stated membership, testing and follow-up information checked September 18, 2026.
17. Hone Health. Treatments for Men. Updated September 9, 2026.
18. GoodRx Help Center. Types of prices: pharmacy membership prices, cash prices and online retail pharmacy prices. Checked September 18, 2026.
19. TRT Provider Guide. How We Review TRT Providers.
20. TRT Provider Guide. Terms of Use. Current commercial-status language checked September 18, 2026.